Enpatoran
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Enpatoran
- Molecular weight
- 320.32
- Structure (SMILES)
- N#Cc1ccc(N2C[C@H](N)C[C@H](C(F)(F)F)C2)c2cccnc12
- enpatoran
- Enpatoran
- ENPATORAN
- enpatoran [INN]
- ENPATORAN [USAN]
- Enpatoran [WHO-DD]
- enpatoran inn
- enpatoran usan
- enpatoran who dd
- m 5049
- M-5049
- m5049
- M5049
- CAS registry numbers
- 2101938-42-3
- ChEMBL ID
- CHEMBL4802159
- InChIKey
- BJXYHBKEQFQVES-NWDGAFQWSA-N
- PubChem compound IDs
- 129240620
- FDA ingredient codes (UNII)
- 7CZ390V26X
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- enpatoran
- Type
- Synthetic organic
- Drug name stem
- -toran
- Action
- Antagonist
- Action type
- Antagonist
- Target
- TLR7
- Gene symbol
- TLR7
- Protein identifier
- Q9NYK1
- Median affinity
- 6
- Affinity units
- pIC50
- Mechanism
- Toll-like receptor 7 antagonist
- Action type
- Antagonist
- Target
- Toll-like receptor 7
- Protein identifier
- Q9NYK1
- Mechanism
- Toll-like receptor 8 antagonist
- Action type
- Antagonist
- Target
- Toll-like receptor 8
- Protein identifier
- Q9NR97
- Mechanism
- Toll-like receptor 7 antagonist
- Action type
- Antagonist
- Target
- Toll-like receptor 7
- Mechanism
- Toll-like receptor 8 antagonist
- Action type
- Antagonist
- Target
- Toll-like receptor 8
- Condition
- Dermatomyositis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000398
- Subject identifier
- D003882
- Condition
- Lupus Erythematosus, Cutaneous
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003834
- Subject identifier
- D008178
- Condition
- Lupus Erythematosus, Systemic
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007915
- Subject identifier
- D008180
- Condition
- COVID-19
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0100096
- Subject identifier
- D000086382
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0003834
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004670
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005282
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007915
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0016367
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0019127
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0019558
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0100096
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 2
- NCT04448756
- NCT04647708
- NCT05540327
- NCT05650567
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 1
- Polar surface area
- 65.94
- Calculated partition coefficient (ALogP)
- 2.82
- Calculated partition coefficient (XLogP)
- 2.7
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 1
- Heavy atoms
- 23
- Molecular formula
- C16H15F3N4
- Monoisotopic mass
- 320.12488098
- Natural product
- No
- Recorded assays
- 7
- Active assays
- 2
Active assay types
- Confirmatory
Related records
Trials (12)
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
- A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants
- Effect of Renal Impairment on Enpatoran Pharmacokinetics
- Enpatoran Human Mass Balance and Absolute Bioavailability Study
- Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants
- Study of M5049 in CLE and SLE Participants
- Study of M5049 in DM and PM Participants (NEPTUNIA)
- Study of M5049 in Healthy Japanese and Caucasian Participants
- Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)
- The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
- The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
In development for (4)
- COVID-19 Phase 2
- Cutaneous lupus erythematosus Phase 1
- Dermatomyositis Phase 2
- Systemic lupus erythematosus Phase 2